First Drug Receives FDA Approval for Aggressive Midline Glioma: Dordaviprone

FDA Approval: Dordaviprone

On 6 August 2025, the FDA announced, for diffuse midline gliomas carrying the H3 K27M mutation , that dordaviprone (Modeyso, Jazz Pharmaceuticals) had received accelerated approval . This approval represents, for this disease, one of the aggressive glioma subtypes , the first licensing of a systemic treatment .

📌 Why Does This Approval Matter?

H3 K27M-mutant diffuse gliomais a brain tumor seen particularly in children and young adults that is highly aggressive and has limited treatment options .

Patients’ median survival is around one year . Until now, there was no effective systemic treatment beyond radiotherapy .

For this reason, FDA approval of dordavipronemarks a historic milestonein the fight against this rare and challenging disease. For the first time, a targeted systemic treatment has been approved for this subtype.

What Is the H3K27M Mutation?

H3K27Mis a mutation in histone H3 at position 27, where lysine (K)is replaced by methionine (M) ; it is a somatic missense mutation.

• It most commonly occurs in the H3F3A (H3.3) and HIST1H3B/C (H3.1) genes.
• Pediatric DMG: Up to 80% · Adult DMG: Up to 60%
• 2021 WHO: Regardless of histology, Grade IV

Clinical Features

• Location: Pons, thalamus, spinal cord (midline).
• Pontine tumors in children: DIPG
• Prognosis: Median overall survival 9–18 months; high mortality at 2 years.
• Standard treatment: Radiotherapy → short-term symptom control; limited response to chemotherapy.
• In adults, tumors may rarely be non-midline/circumscribed; complete resection may prolong survival.

Biological Mechanism

Normal: H3K27me3 → gene silencing · H3K27ac → gene activation

H3K27M → PRC2 inhibition → global loss of H3K27me3 + increased H3K27ac

• Oncogene transcription increases (MYC, MCL-1 etc.)
• OPC differentiation is blocked → cells proliferate without maturing
• Effects are enhanced by mutations such as ACVR1, PDGFRA, TP53 .

Epigenetic Features

• ↓ H3K27me3, ↑ H3K27ac → chromatin accessibility increases
• BRD2/4 is recruited to super-enhancer regions → oncogene transcription increases
• CDKN2A and other tumor suppressor loci may be further repressed

Immunological Features

• ‘Immune-cold’ microsite: low NK/T-cell infiltration, predominance of M2 macrophages
• PD-L1 is generally low → limited response to immunotherapy
• Opportunity: differentiation-based immune approaches

Frequently Co-Occurring Genetic Alterations

Pediatric – Adult – Conventional GBM Comparison

Practical Summary: H3K27M is a critical prognostic biomarker, particularly in pediatric and adult midline gliomas . In conventional hemispheric GBM, it is rare and does not constitute a routine subgroup.

📄 Basis for Approval

Approval is based on a pooled analysis involving previously irradiated patients with recurrent disease: 50 patients (46 adults, 4 children) from 5 separate single-arm studies .

In the patients’ tumors, the H3 K27M mutationwas confirmed by immunohistochemistry or genetic sequencing.

📊 Clinical Findings

• Overall Response Rate: 22%
• Median Response Time: 8.3 months
• Duration of Response (DOR): 10.3 months
• 73%maintained response for ≥6 months, and 27%for ≥12 months

💚 Effects on Quality of Life

• Among 15 patients, 46.7% reduced their corticosteroid dose by 50%
• Among 34 patients, 20.6% had improved performance status

⚠️ Adverse Effects and Safety

• Most common adverse effects: Fatigue (34%), nausea (18%), lymphocytopenia (14%)
• Grade 3 adverse effects: 20%, most commonly: fatigue (10%)
• Serious adverse effects: Hydrocephalus (8%), severe nausea (8%), seizure, pulmonary embolism
• Warnings: Hypersensitivity, QTc prolongation, fetal toxicity

🌟 Looking Ahead

To define dordaviprone’s potential more clearly, Phase 3 trials remain ongoing.

This development opens a new door of hope for a rare and aggressive brain tumor.